Connect Biopharma's Rademikibart Shows Promising Results in Phase 2 Asthma Trial — Connect Biopharma Holdings Limited

Event summary

Connect Biopharma's Phase 2 Seabreeze STAT Asthma study showed Rademikibart reduced treatment failure rate by 66% over 28 days compared to placebo.
Rademikibart demonstrated a statistically significant improvement in lung function (FEV1) at Day 7, with a 250 mL increase compared to 120 mL with placebo.
The study enrolled 160 patients globally, with Rademikibart being well-tolerated and showing a low incidence of adverse events.
Connect Biopharma plans to report topline data from its Phase 2 Seabreeze STAT COPD study later this month and engage with the FDA regarding a Phase 3 program.

The big picture

Connect Biopharma's positive Phase 2 data for Rademikibart positions it as a potential best-in-class treatment for acute exacerbations in asthma patients with type 2 inflammation. The results highlight the drug's ability to rapidly improve lung function and reduce treatment failure rates, addressing a critical gap in current standard-of-care therapies. The upcoming engagement with the FDA and the planned Phase 3 program will be key milestones in determining the drug's commercial potential.

What we're watching

Regulatory Alignment: Whether Connect Biopharma can secure FDA alignment on a Phase 3 program for Rademikibart, which will be crucial for its regulatory pathway.
Market Potential: The pace at which Rademikibart can address the significant unmet need in treating acute exacerbations of asthma and COPD, given the high number of emergency department visits.
Clinical Efficacy: How the upcoming Phase 2 COPD study results will compare to the asthma trial, and whether they will support the broader potential of Rademikibart.